Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Angi Inc (ANGI) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Angi Inc vs Citius Pharmaceuticals Inc — how do they compare? Angi Inc trades at $4.43 (market cap $182.30M), while Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M). The key difference: Angi Inc is far larger — about 9.1× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Angi Inc nearer its low. Which is the better fit depends on your goals.

ANGICTXR
Market Cap
$182.30M$20.01M
Sector
MediaHealth
52-Week High
$18.46$1.82
52-Week Low
$4.49$0.48
Enterprise Value
$392.07M$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Angi Inc

ANGI trades at $4.59, down 5.17% on the day, reflecting ongoing operational challenges. The stock is in a bearish technical trend, with revenue declining from $1.03B in 2025 to a projected $993M in 2026. Recent Q2 2026 earnings missed expectations significantly, with an EPS of -$5.7 versus an expected $0.1333, highlighting deep profitability issues. Negative net income margins and cash flow concerns persist, though valuation ratios like P/S of 0.19 and P/B of 0.27 appear low.

The outlook remains cautious due to accelerating user churn, revenue declines, and lack of clear catalysts. Analyst consensus is a Hold with a $7.00 price target, but risks include ongoing fraud investigations, competitive pressures, and negative cash flow trends. Upside potential exists if the company stabilizes its platform, but current fundamentals suggest continued headwinds for shareholder value.

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Angi Inc

Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. It has two geographical segments namely North America (the United States and Canada), which primarily includes the operations HomeAdvisor, Angie's List, Handy, mHelpDesk, HomeStars, and Fixd Repair

Read more on ANGI

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR